Clinical trial
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
NCT00001959 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00001959 |
|---|---|
| Title | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) |
| Official title | Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria |
| Intervention type | Drug |
| Interventions | Pirfenidone |
| Enrollment | 21 |
| Start date | Dec 1, 1999 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 19, 2000 |
| Last update posted | May 26, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: